Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tabalumab |
Synonyms | |
Therapy Description |
Tabalumab (LY2127399) is a monoclonal antibody that neutralizes B-cell activating factor (BAFF), resulting in decreased development of osteoclasts and thus, potential antitumor activity (PMID: 27287072, PMID: 28005265). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tabalumab | LY2127399 | Tabalumab (LY2127399) is a monoclonal antibody that neutralizes B-cell activating factor (BAFF), resulting in decreased development of osteoclasts and thus, potential antitumor activity (PMID: 27287072, PMID: 28005265). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|